A strain of Corynebacterium glutamicum that enhances heterologous acetyllactate synthase expression and its application in the production of L-isoleucine.
By integrating heterologous acetolactate synthase genes from Pseudomonas aeruginosa or Escherichia coli into Corynebacterium glutamicum, the fermentation process was optimized, solving the problems of low acid production, long cycle, and genetic instability in the production of L-isoleucine in the existing technology. This resulted in efficient and stable L-isoleucine production and reduced production costs.
Patent Information
- Application Number
- CN202611428456.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-15
- Publication Date
- 2026-11-10
AI Technical Summary
In existing technologies, wild-type strains have drawbacks in producing L-isoleucine, such as low acid production, numerous byproducts, and long fermentation cycles, resulting in high costs for downstream separation and purification. Furthermore, strains modified based on plasmid expression or resistance markers suffer from genetic instability and poor scale-up effects, making it difficult to achieve low-cost, high-intensity, and stable production.
By integrating heterologous acetolactate synthase genes from Pseudomonas aeruginosa or Escherichia coli into Corynebacterium glutamicum, its expression in Corynebacterium glutamicum was enhanced, the fermentation process was optimized to improve the yield and conversion rate of L-isoleucine, and the adaptability and stability of the strain were enhanced by adopting a non-resistance genome integration strategy.
It significantly improved the fermentation yield and conversion rate of L-isoleucine, reduced production costs, and achieved efficient and stable L-isoleucine production, meeting the requirements of environmental protection and cost indicators.
Smart Images

Figure FT_1 
Figure SMS_1 
Figure SMS_2
Abstract
Description
Technical Field
[0001] This invention relates to the field of genetic engineering technology, specifically to a Corynebacterium glutamicum that enhances the expression of heterologous acetyllactate synthase and its application in the production of L-isoleucine. Background Technology
[0002] L-Isoleucine is an essential branched-chain amino acid that animals and humans cannot synthesize. Global annual consumption exceeds 60,000 tons, with approximately 70% used in high-end animal feed, and the remainder used as a raw material for intravenous infusions, sports nutrition, antibiotic precursors, and special medical foods. The market maintains an annual growth rate of over 6%. Compared to chemical synthesis and enzymatic methods, microbial fermentation uses renewable sugars as raw materials to generate the target product, offering a greener and lower-cost process, and has become the mainstream approach. However, wild-type strains generally suffer from low acid production levels, numerous byproducts, and long fermentation cycles, leading to high downstream separation and purification costs. The industry average sugar-acid conversion rate is less than one-quarter, making it difficult to meet increasingly stringent environmental and cost requirements.
[0003] In recent years, with the maturation of systems biology and metabolic engineering technologies, researchers have begun to target and modify traditional production strains. By relieving end-product feedback inhibition, optimizing intracellular redox balance, and enhancing product efflux, fermentation indicators for isoleucine have been significantly improved, with laboratory levels exceeding 50 g / L and conversion rates increased by approximately 50%, laying the foundation for industrial scale-up. However, existing technologies largely rely on plasmid expression or resistance markers, which suffer from genetic instability and poor scale-up effects, falling short of truly low-cost, high-intensity, and stable production. Therefore, developing a strain modification strategy that is resistance-free, genome-integrated, and highly adaptable, along with corresponding fermentation and separation processes, is crucial for enhancing the competitiveness of the isoleucine industry and provides ample space for related patent development.
[0004] Acetolactate synthase can catalyze two parallel reactions: first, the condensation of 3 molecules of pyruvate to generate acetolactate, which ultimately synthesizes valine and leucine; second, the catalysis of 1 molecule of pyruvate and 2 molecules of 2-ketobutyrate to generate acetylhydroxybutyrate, which ultimately synthesizes isoleucine. This is the key rate-limiting step in the biosynthetic pathway of branched-chain amino acids (leucine, isoleucine, valine). Summary of the Invention
[0005] The purpose of this invention is to provide a Corynebacterium glutamicum that enhances the expression of heterologous acetyllactate synthase and its application in the production of L-isoleucine.
[0006] In a first aspect, the present invention claims protection for a recombinant Corynebacterium glutamicum.
[0007] The recombinant Corynebacterium glutamicum claimed in this invention includes the expression of heterologous acetolactate synthase; said heterologous acetolactate synthase is acetolactate synthase derived from Pseudomonas aeruginosa or acetolactate synthase derived from Escherichia coli.
[0008] Furthermore, the recombinant Corynebacterium glutamicum claimed in this invention expresses both its own endogenous acetolactate synthase and the aforementioned heterologous acetolactate synthase.
[0009] Furthermore, the acetolactate synthase derived from *Pseudomonas aeruginosa* comprises (or is) any one of the following (A1)-(A4): (A1) is composed of a large catalytic subunit whose amino acid sequence contains (or is) SEQ ID NO:2 and a small regulatory subunit whose amino acid sequence contains (or is) SEQ ID NO:3; (A2) is formed by the catalytic large subunit and the regulatory small subunit defined by (A1) through the substitution, deletion and / or addition of one or more amino acid residues, and retains the acetolactate synthase activity of the large and small subunits. (A3) consists of a large subunit and a small subunit that have at least 90% sequence identity with the amino acid sequence defined by (A1) or (A2) and retain acetolactate synthase activity; (A4) consists of two fusion proteins obtained by linking tag sequences to the N-terminus and / or C-terminus of the large and small subunits as defined in any of (A1) to (A3).
[0010] Furthermore, the acetolactate synthase derived from *E. coli* comprises (or is) any one of the following (B1)-(B4): (B1) is composed of a large catalytic subunit whose amino acid sequence contains (or is) SEQ ID NO:5 and a small regulatory subunit whose amino acid sequence contains (or is) SEQ ID NO:6; (B2) is formed by replacing, deleting and / or adding one or more amino acid residues of the catalytic large subunit and the regulatory small subunit defined in (B1), and retaining the acetolactate synthase activity of the large and small subunits. (B3) consists of a large subunit and a small subunit that have at least 90% sequence identity with the amino acid sequence defined by (B1) or (B2) and retain acetolactate synthase activity. (B4) consists of two fusion proteins obtained by linking tag sequences to the N-terminus and / or C-terminus of the large and small subunits as defined in any of (B1) to (B3).
[0011] In the proteins defined in (A3) and (B3) above, identity refers to the identity of the amino acid sequence. The identity of amino acid sequences can be determined using identity search sites on the Internet, such as the BLAST page on the NCBI homepage. For example, in Advanced BLAST 2.1, using blastp as the program, setting the Expect value to 10, setting all filters to OFF, using BLOSUM62 as the matrix, setting the Gap existence cost, Per residue gap cost, and Lambda ratio to 11, 1, and 0.85 (default values) respectively, and performing an identity search on a pair of amino acid sequences, the identity value (%) can then be obtained.
[0012] In the aforementioned proteins, the at least 90% sequence identity can be at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity.
[0013] Furthermore, the recombinant Corynebacterium glutamicum comprises: a recombinant bacterium obtained by introducing the encoding gene of the heterologous acetolactate synthase into a recipient Corynebacterium glutamicum. In some embodiments of the present invention, the recombinant Corynebacterium glutamicum is obtained by introducing the encoding gene of the heterologous acetolactate synthase into a recipient Corynebacterium glutamicum. The recipient Corynebacterium glutamicum normally expresses its own acetolactate synthase.
[0014] The gene encoding heterologous acetolactate synthase may include any of the following: (C1) A DNA molecule whose nucleotide sequence contains (or is) SEQ ID NO:1 (corresponding to the encoding gene of acetolactate synthase from Pseudomonas aeruginosa) or whose nucleotide sequence contains (or is) SEQ ID NO:4 (corresponding to the encoding gene of acetolactate synthase from Escherichia coli). (C2) A DNA molecule that hybridizes under stringent conditions with the DNA molecule defined by (C1) and encodes the heterologous acetolactate synthase; The DNA molecule that has 99%, 95%, 90%, 85% or more or 80% identity with the DNA sequence defined by (C3) and (C1) or (C2) and encodes the heterologous acetolactate synthase.
[0015] The stringent conditions for the above-mentioned genes can be as follows: hybridization at 50°C in a mixed solution of 7% sodium dodecyl sulfate (SDS), 0.5M Na3PO4, and 1mM EDTA, followed by rinsing at 50°C in 2×SSC and 0.1% SDS; or hybridization at 50°C in a mixed solution of 7% SDS, 0.5M Na3PO4, and 1mM EDTA, followed by rinsing at 50°C in 1×SSC and 0.1% SDS; or hybridization at 50°C in a mixed solution of 7% SDS, 0.5M Na3PO4, and 1mM EDTA, followed by rinsing at 50°C in 0.5×SSC and 0.1% SDS; or hybridization at 50°C in a mixed solution of 7% SDS, 0.5M Na3PO4, and 1mM EDTA, followed by rinsing at 50°C in 0.1 ...7% SDS, 0.5M Na3PO4, and 1mM EDTA; or hybridization at 50°C in a mixed solution of 7% SDS, 0.5M Na3PO4, and 1mM EDTA, followed by rinsing at 50°C in 0.1×SSC and 0.1% SDS. Hybridize in a mixed solution of SDS, 0.5 M Na3PO4 and 1 mM EDTA, and wash at 65 °C with 0.1 × SSC and 0.1% SDS; alternatively, hybridize in a solution of 6 × SSC and 0.5% SDS at 65 °C, and then wash once each with 2 × SSC and 0.1% SDS and 1 × SSC and 0.1% SDS.
[0016] For the genes mentioned above, nucleotide sequence identity can be determined using identity search sites on the Internet, such as the BLAST page on the NCBI homepage. For example, in Advanced BLAST 2.1, using blastn as the program, setting the Expect value to 10, setting all filters to OFF, using BLOSUM62 as the matrix, setting the Gap existence cost, Per residue gap cost, and Lambda ratio to 11, 1, and 0.85 (default values) respectively, and performing an identity search on a pair of nucleotide sequences to calculate the identity value (%), then the identity value can be obtained.
[0017] In the aforementioned genes, the 80% or more identity can be at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity. The 85% or more identity can be at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity. The 90% or more identity can be at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity. The 95% or more identity can be at least 95%, 96%, 97%, 98%, or 99% identity.
[0018] In some embodiments of the present invention, the recombinant Corynebacterium glutamicum is a recombinant bacterium obtained by replacing the segment located between SEQ ID NO:16 and SEQ ID NO:17 (i.e., the coding region of the poxB gene) in the genome of the recipient Corynebacterium glutamicum with the segment shown in SEQ ID NO:18 (i.e., the coding gene for acetolactate synthase derived from Pseudomonas aeruginosa and the trc promoter fragment). Further, other sequences remain unchanged.
[0019] In other embodiments of the present invention, the recombinant Corynebacterium glutamicum is a recombinant bacterium obtained by replacing the segment located between SEQ ID NO:16 and SEQ ID NO:17 (i.e., the coding region of the poxB gene) in the genome of the recipient Corynebacterium glutamicum with the segment shown in SEQ ID NO:19 (i.e., the coding gene for acetolactate synthase derived from the Escherichia coli and the trc promoter fragment). Further, other sequences remain unchanged.
[0020] Secondly, the present invention claims protection for the use of the recombinant Corynebacterium glutamicum described in the first aspect above in the fermentation production of L-isoleucine.
[0021] Thirdly, the present invention claims protection for the use of heterologous acetolactate synthase or related biological materials in the preparation or production of L-isoleucine; wherein the heterologous acetolactate synthase is acetolactate synthase derived from Pseudomonas aeruginosa or acetolactate synthase derived from Escherichia coli.
[0022] The relevant biological material may include or be any of the following: the encoding gene of the heterologous acetolactate synthase or an expression cassette containing the encoding gene or a recombinant vector or recombinant microorganism or recombinant cell.
[0023] The acetolactate synthase derived from *Pseudomonas aeruginosa* comprises (or is) any one of (A1)-(A4) above. The acetolactate synthase derived from *Escherichia coli* comprises (or is) any one of (B1)-(B4) below.
[0024] Furthermore, the preparation or production of L-isoleucine involves fermentation of L-isoleucine using Corynebacterium glutamicum.
[0025] Fourthly, the present invention claims a method for constructing engineered bacteria for the production of L-isoleucine.
[0026] The method for constructing engineered bacteria for producing L-isoleucine, as claimed in this invention, may include the following steps: expressing heterologous acetolactate synthase in a recipient, Corynebacterium glutamicum; wherein the heterologous acetolactate synthase is acetolactate synthase derived from Pseudomonas aeruginosa or acetolactate synthase derived from Escherichia coli.
[0027] The acetolactate synthase derived from *Pseudomonas aeruginosa* comprises (or is) any one of (A1)-(A4) above. The acetolactate synthase derived from *Escherichia coli* comprises (or is) any one of (B1)-(B4) below.
[0028] Fifthly, the present invention claims a method for producing L-isoleucine.
[0029] The method for producing L-isoleucine claimed in this invention may include the following steps: fermenting and culturing the recombinant Corynebacterium glutamicum described in the first aspect above to obtain L-isoleucine from the fermentation product.
[0030] The cultivation of the recombinant Corynebacterium glutamicum can be carried out by methods known to those skilled in the art using existing techniques, and the fermentation method can also be optimized and improved through routine experiments. The fermentation can be carried out under fermentation conditions known in the art in a suitable culture medium. The culture medium may contain: a carbon source, a nitrogen source, trace elements, and combinations thereof. During cultivation, the pH of the culture can be adjusted. During cultivation, the temperature of the culture can be controlled. During cultivation, the rotation speed can be controlled. During cultivation, the fermentation time can be controlled. During cultivation, dissolved oxygen can be controlled.
[0031] In some embodiments of the present invention, the specific culture medium formulation and fermentation process used are described in the relevant sections of Examples 2 and 3.
[0032] In the foregoing related aspects, in some embodiments of the present invention, the *Corynebacterium glutamicum* (or the *Corynebacterium glutamicum* receptor) is *Corynebacterium glutamicum* (… Corynebacterium glutamicumCGMCC No. 20437. In some other embodiments of the present invention, the Corynebacterium glutamicum (or the recipient Corynebacterium glutamicum) is Corynebacterium glutamicum ATCC13032.
[0033] To enhance the affinity of acetolactate synthase for α-ketobutyrate and reduce feedback inhibition, this invention strengthens the carbon flux branch for isoleucine entry by integrating a heterologous acetolactate synthase operon into the genome of *Corynebacterium glutamicum*. Experiments have demonstrated that integrating the encoding gene for acetolactate synthase from *Pseudomonas aeruginosa* or *Escherichia coli* into the genome of the recipient *Corynebacterium glutamicum* produces a more cost-effective L-isoleucine fermentation strain. This invention is of great significance for improving the fermentation yield of L-isoleucine.
[0034] Deposit Description Classification and nomenclature: Corynebacterium glutamicum ( Corynebacterium glutamicum ); Biological material used for ginseng: YPILE001 Preservation institution: China General Microbiological Culture Collection Center, China Committee on the Preservation and Management of Microbial Cultures; The abbreviation for the depository institution is CGMCC. Address: No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing; Date of deposit: August 17, 2020; Registered with the China National Collection Center (CGMCC) No. 20437. Attached Figure Description
[0035] Figure 1 The acetolactate synthase activity of each strain is shown. Detailed Implementation
[0036] The present invention will now be described in further detail with reference to specific embodiments. The given embodiments are merely illustrative of the invention and not intended to limit its scope. The embodiments provided below can serve as a guide for further improvements by those skilled in the art and do not constitute a limitation on the invention in any way.
[0037] Unless otherwise specified, the experimental methods used in the following examples are conventional methods, performed according to the techniques or conditions described in the literature in this field or according to the product instructions. Unless otherwise specified, the materials and reagents used in the following examples are commercially available.
[0038] The strains used in the following examples: Corynebacterium glutamicum ( Corynebacterium glutamicumCGMCC No. 20437, also known as Corynebacterium glutamicum CGMCC20437, is a strain that has been deposited through a patent procedure with the accession number CGMCC No. 20437.
[0039] Corynebacterium glutamicum ATCC13032 is a product of the American Type Culture Collection (ATCC), with strain number 13032.
[0040] Pseudomonas aeruginosa ( Pseudomonas aeruginosa The strain originated from Beijing Beina Innovation Biotechnology Research Institute (BNCC), with strain number BNCC337940.
[0041] Escherichia coli ( Escherichia coli MG1655 was derived from Beijing Beina Innovation Biotechnology Research Institute (BNCC), strain number: BNCC363342.
[0042] Klebsiella pneumoniae ( Klebsiella pneumoniae The strain originated from Beijing Beina Innovation Biotechnology Research Institute (BNCC), with strain number BNCC102997.
[0043] Serratia marcescens ( Serratia marcescen The strain (s) originated from Beijing Beina Innovation Biotechnology Research Institute (BNCC), with strain number BNCC186186.
[0044] Mycobacterium tuberculosis ( Mycobacterium tuberculosis The strain was obtained from the American Type Culture Collection (ATCC) and its strain number is 25618.
[0045] Unless otherwise specified, the quantitative experiments in the following examples were performed in triplicate, and the results were averaged.
[0046] Example 1: Detection of heterologous acetolactate synthase activity Five bacterial strains—Pseudomonas aeruginosa, Escherichia coli MG1655, Klebsiella pneumoniae, Serratia marcescens, and Mycobacterium tuberculosis—were revived and activated. Each activated strain was then transferred to fresh culture medium at a 1% (v / v) inoculation rate and cultured under appropriate conditions. Every 1 hour, samples were taken to measure the absorbance at 600 nm to plot growth curves. Based on the time point at which each strain entered the logarithmic growth phase, the bacteria were cultured to the logarithmic growth phase. The collected bacterial pellets were then analyzed and enzyme activity calculated using the acetolactate synthase activity assay kit (Shanghai Shangbao Biotechnology Co., Ltd., catalog number: BA2881) to screen for heterologous microorganisms with high acetolactate synthase activity.
[0047] The detection principle of acetolactate synthase activity is as follows: acetolactate synthase catalyzes the formation of acetolactate from pyruvate. Under certain conditions, acetolactate is decarboxylated to form acetoin. Acetolactate reacts with creatine and α-naphthol in an alkaline environment to form a red substance with a maximum absorbance at 525 nm.
[0048] Enzyme activity test results as follows Figure 1 As shown in the figure, the acetolactate synthase from Pseudomonas aeruginosa has the highest enzyme activity, reaching 320 U / h / mg (one unit of enzyme activity is defined as the production of 1 nmol of acetolactate per hour per mg of tissue protein at 37℃), while the acetolactate synthase from Escherichia coli has an enzyme activity of 208.2 U / h / mg.
[0049] Example 2: Construction of an engineered strain overexpressing a heterologous acetyllactate synthase gene in its genome. Vectors were constructed using NEBuilder recombination technology, based on the *Pseudomonas aeruginosa* strains published by NCBI. Pseudomonas aeruginosa The genome sequence of Pseudomonas aeruginosa (GenBank:CP172857.1, 2024-11-10) was obtained, and primers for amplifying the Pseudomonas aeruginosa ilvIH gene (sequence shown in SEQ ID NO:1, positions 1-1725 of SEQ ID NO:1 encode the ilvI protein shown in SEQ ID NO:2, and positions 1728-2219 of SEQ ID NO:1 encode the ilvH protein shown in SEQ ID NO:3) were designed and synthesized.
[0050] According to Escherichia coli ( Escherichia coli The genome sequence of MG1655 (GenBank:NC_000913.3, 2025-12-09) was used to design and synthesize primers for amplifying the Escherichia coli ilvIH gene (sequence shown in SEQ ID NO:4, positions 1-1725 of SEQ ID NO:4 encode the ilvI protein shown in SEQ ID NO:5, and positions 1728-2219 of SEQ ID NO:4 encode the ilvH protein shown in SEQ ID NO:6).
[0051] According to Klebsiella pneumoniae ( Klebsiella pneumoniae The genome sequence of Klebsiella pneumoniae (GenBank:CP003200.1, 2017-03-22) was obtained, and primers for amplifying the ilvIN gene (sequence shown in SEQ ID NO:7, positions 1-1701 of SEQ ID NO:7 encode the ilvI protein shown in SEQ ID NO:8, and positions 1674-2195 of SEQ ID NO:7 encode the ilvN protein shown in SEQ ID NO:9) were designed and synthesized.
[0052] According to Serratia marcescens ( Serratia marcescens The genome sequence of Serratia marcescens (GenBank: CP127881.1, 2023-06-20) was obtained, and primers for amplifying the plasmid ilvIN gene of Serratia marcescens (sequence shown in SEQ ID NO:10, positions 1-1719 of SEQ ID NO:10 encode the ilvI protein shown in SEQ ID NO:11, and positions 1722-2213 of SEQ ID NO:10 encode the ilvN protein shown in SEQ ID NO:12) were designed and synthesized.
[0053] According to Mycobacterium tuberculosis ( Mycobacterium tuberculosis The genome sequence of Mycobacterium tuberculosis (GenBank: AL123456.3, 2015-02-27) was used to design and synthesize primers for amplifying the ilvB1 and ilvN genes (sequences shown in SEQ ID NO:13, positions 1-1857 of SEQ ID NO:13 encode the ilvB1 protein as shown in SEQ ID NO:14, and positions 1857-2363 of SEQ ID NO:13 encode the ilvN protein as shown in SEQ ID NO:15).
[0054] The above genes were overexpressed in Corynebacterium glutamicum CGMCC No.20437 and ATCC 13032 via homologous recombination.
[0055] The primers were designed as follows (synthesized by Invitrogen Shanghai), and the nucleotide sequences in lowercase format are the sequences on the pK18mobsacB plasmid: P1: 5'-cagtgccaagcttgcatgcctgcaggtcgactctagCATTGCCATCAATCCATGC-3'; P2: 5'-TTTCTCTAGACATTATACGAGCCGGATGATTAATTGTCAATGATTGATACACCTGCTGTT-3'; P3: 5'-CCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTTGCTGAACTCCTCAACGTTATGGC-3'; P4: 5'-cagctatgaccatgattacgaattcgagctcggtacccGCACCAAGTGAAGCGATTC-3'; P5: 5'-ATCCGGCTCGTATAATGTCTAGAGAAAGAGGAGAAATACTAGGTGGAGCTTTTATCTGGCGCTGA-3'; P6: 5'-GACCCGTTTAGAGGCCCCAAGGGGTTATGCTAGTCAGATGCTCAGAGTCTTGTCGCC-3'; P7: 5'-CTCGTATAATGTCTAGAGAAAGAGGAGAAATACTAGATGGAGATGTTGTCTGGAGCCGAGATG-3'; P8: 5'-CCCGTTTAGAGGCCCCAAGGGGTTATGCTAGTCAACGCATTATTTTATCGCCGCGAAA-3'; P9: 5'-GCTCGTATAATGTCTAGAGAAAGAGGAGAAATACTAGATGGTCGTCCAATCGCTTGTCGATCAG-3'; P10: 5'-GACCCGTTTAGAGGCCCCAAGGGGTTATGCTAGTTAGCGCATGATTTTATCACCGCGAGACA-3'; P11: 5'-CTCGTATAATGTCTAGAGAAAGAGGAGAAATACTAGATGGAGATGTTGTCAGGAGCCGAGATGG-3'; P12: 5'-GACCCGTTTAGAGGCCCCAAGGGGTTATGCTAGTCAGCGCATGATTTTGTCGCCGCG-3'; P13: 5'-GGCTCGTATAATGTCTAGAGAAAGAGGAGAAATACTAGGTGAGCGCACCAACCAAGCCAC-3'; P14: 5'-GACCCGTTTAGAGGCCCCAAGGGGTTATGCTAGCTACTTGGCGGTGCCGATGCCGCGCGG-3'.
[0056] Using the genomic DNA of Corynebacterium glutamicum ATCC 13032 as a template, PCR amplification was performed with primers P1 and P2 to obtain an 880 bp upstream homologous arm fragment of the poxB gene (sequence shown in SEQ ID NO:16); PCR amplification was performed with primers P3 and P4 to obtain an 835 bp downstream homologous arm fragment of poxB (sequence shown in SEQ ID NO:17).
[0057] Using Pseudomonas aeruginosa genomic DNA as a template, PCR amplification was performed with primers P5 and P6 to obtain the ilvIH gene and a 2294 bp trc promoter fragment (sequence shown in SEQ ID NO:18).
[0058] With Escherichia coli ( Escherichia coli Using MG1655 genomic DNA as a template, PCR amplification was performed with primers P7 and P8 to obtain the ilvIH gene and a 2286 bp trc promoter fragment (sequence shown in SEQ ID NO:19).
[0059] Klebsiella pneumoniae ( Klebsiella pneumoniae Using genomic DNA as a template, PCR amplification was performed with primers P9 and P10 to obtain the ilvIN gene and a 2265 bp trc promoter fragment (sequence shown in SEQ ID NO:20).
[0060] Serratia marcescens ( Serratia marcescens Using genomic DNA as a template, PCR amplification was performed with primers P11 and P12 to obtain the ilvIN gene and a 2282 bp trc promoter fragment (sequence shown in SEQ ID NO:21).
[0061] With Mycobacterium tuberculosis ( Mycobacterium tuberculosis Using genomic DNA as a template, PCR amplification was performed with primers P13 and P14 to obtain the ilvB1 gene, ilvN gene, and a 2434 bp trc promoter fragment (sequence shown in SEQ ID NO:22).
[0062] After the PCR reaction, all amplified fragments were recovered by electrophoresis using a column-based DNA gel extraction kit. The acetolactate synthase gene fragments from the five heterologous microorganisms were combined with upstream and downstream homologous arm fragments of the poxB gene, respectively. The three fragments from each combination were then ligated with pK18mobsacB plasmid purified after Xbal I / BamHI digestion using NEBuilder enzyme (NEB) at 50°C for 30 minutes. After the ligation product was transformed into DH5α, the resulting single clones were identified by PCR using M13 primers (M13F: 5'-TGTAAAACGACGGCCAGT-3'; M13R: 5'-CAGGAAACAGCTATGACC-3') to obtain positive integration plasmids (recombinant vectors). The five different insert fragments of the recombinant plasmids were named pK18-ilvIHOE-Pa, pK18-ilvIHOE-Ec, pK18-ilvINOE-Kp, pK18-ilvINOE-Sm, and pK18-ilvB1NOE-Mt, respectively. These positive integration plasmids contained kanamycin resistance markers, and recombinants integrated into the genome could be obtained through kanamycin screening.
[0063] The PCR reaction system consisted of: 5 μL of 10×Ex Taq Buffer, 4 μL of dNTP Mixture (2.5 mM each), and Mg... 2+ 4 μL of (25 mM) primers, 2 μL each of (10 pM) primers, 0.25 μL of Ex Taq (5 U / μL), and ddH2O added to a total volume of 50 μL.
[0064] The PCR reaction program was as follows: 94 °C pre-denaturation for 5 min; 94 °C denaturation for 30 s, 52 °C annealing for 30 s, 72 °C extension for 60 s (30 cycles); 72 °C final extension for 10 min.
[0065] The recombinant vector pK18-ilvIHOE-Pa contains the "ilvIH gene and trc promoter fragment from Pseudomonas aeruginosa" shown in SEQ ID NO:18. The nucleotide sequence of the ilvIH gene from Pseudomonas aeruginosa is shown in SEQ ID NO:1. This sequence encodes the ilvI protein (acetolactate synthase catalytic large subunit) shown in SEQ ID NO:2 and the ilvH protein (acetolactate synthase regulatory small subunit) shown in SEQ ID NO:3.
[0066] The recombinant vector pK18-ilvIHOE-Ec contains the "ilvIH gene and trc promoter fragment from E. coli" shown in SEQ ID NO:19. The nucleotide sequence of the ilvIH gene from E. coli is shown in SEQ ID NO:4. This sequence encodes the ilvI protein (acetolactate synthase catalytic large subunit) shown in SEQ ID NO:5 and the ilvH protein (acetolactate synthase regulatory small subunit) shown in SEQ ID NO:6.
[0067] The recombinant vector pK18-ilvINOE-Kp contains the "ilvIN gene and trc promoter fragment from Klebsiella pneumoniae" shown in SEQ ID NO:20. The nucleotide sequence of the ilvIN gene from Klebsiella pneumoniae is shown in SEQ ID NO:7. This sequence encodes the ilvI protein (acetolactate synthase catalytic large subunit) shown in SEQ ID NO:8 and the ilvN protein (acetolactate synthase regulatory small subunit) shown in SEQ ID NO:9.
[0068] The recombinant vector pK18-ilvINOE-Sm contains the "ilvIN gene and trc promoter fragment from Serratia marcescens" shown in SEQ ID NO:21. The nucleotide sequence of the ilvIN gene from Serratia marcescens is shown in SEQ ID NO:10. This sequence encodes the ilvI protein (the large catalytic subunit of acetolactate synthase) shown in SEQ ID NO:11 and the ilvN protein (the small regulatory subunit of acetolactate synthase) shown in SEQ ID NO:12.
[0069] The recombinant vector pK18-ilvB1NOE-Mt contains the "ilvB1 gene, ilvIN gene and trc promoter fragment from Mycobacterium tuberculosis" shown in SEQ ID NO:22. The nucleotide sequences of the ilvB gene and ilvIN gene from Mycobacterium tuberculosis are shown in SEQ ID NO:13. This sequence encodes the ilvB1 protein (acetolactate synthase catalytic large subunit) shown in SEQ ID NO:14 and the ilvN protein (acetolactate synthase regulatory small subunit) shown in SEQ ID NO:15.
[0070] Each correctly sequenced integration plasmid (pK18-ilvIHOE-Pa, pK18-ilvIHOE-Ec, pK18-ilvINOE-Kp, pK18-ilvINOE-Sm, and pK18-ilvB1NOE-Mt) was electroporated into Corynebacterium glutamicum CGMCC No.20437 and ATCC 13032, respectively, and cultured in culture medium. The composition and culture conditions of the culture medium are shown in Table 1.
[0071] Table 1. Composition and culture conditions of the culture medium
[0072] Single colonies generated from the culture of the pK18-ilvIHOE-Pa recombinant plasmid were identified by PCR using primers P15 / P16. Strains amplified with a 1108 bp fragment were considered positive, while those without amplification were considered the original strain. Positive strains were cultured on 15% sucrose medium, and single colonies were further identified by PCR using primers P17 / P18. Strains amplified with a 1151 bp fragment were considered positive. Positive strains of *Pseudomonas aeruginosa* with the *ilvIH* gene integrated into *Corynebacterium glutamicum* CGMCC No. 20437 and ATCC 13032 were named YPI-001 and YPI-002, respectively.
[0073] Both recombinant bacteria YPI-001 and YPI-002 contain the ilvIH gene (as shown in SEQ ID NO:1) derived from *Pseudomonas aeruginosa*. Specifically, recombinant bacteria YPI-001 is obtained by replacing the coding region of the poxB gene (GeneID: 1020557, 12-Dec-2025. Note: *C. glutamicum* CGMCC 20437 was derived from *C. glutamicum* ATCC 13032, and the poxB gene coding region was not edited, therefore the sequence at this point is consistent with ATCC13032) (i.e., the fragment located between SEQ ID NO:16 and SEQ ID NO:17) from *P. aeruginosa* with the ORF and trc promoter region of the ilvIH gene (i.e., SEQ ID NO:18), while keeping other nucleotides in the genome of *C. glutamicum* CGMCC No.20437 unchanged. The recombinant strain YPI-002 is obtained by replacing the coding region of the poxB gene (GeneID: 1020557, 12-Dec-2025) in the genome of Corynebacterium glutamicum ATCC 13032 (i.e., the fragment located between SEQ ID NO:16 and SEQ ID NO:17) with the ORF of the ilvIH gene and the trc promoter region (i.e., SEQ ID NO:18) from Pseudomonas aeruginosa, while keeping other nucleotides in the genome of Corynebacterium glutamicum ATCC 13032 unchanged.
[0074] Single colonies generated from the culture of the pK18-ilvIHOE-Ec recombinant plasmid were identified by PCR using primers P15 / P19. Strains amplified with a fragment of 1108 bp were considered positive, while those without amplification were considered the original strain. Positive strains were cultured on medium containing 15% sucrose, and single colonies were further identified by PCR using primers P20 / P18. Strains amplified with a fragment of 1151 bp were considered positive. Positive strains of *E. coli* with the ilvIH gene integrated into *Corynebacterium glutamicum* CGMCC No. 20437 and ATCC 13032 were named YPI-003 and YPI-004, respectively.
[0075] Both recombinant bacteria YPI-003 and YPI-004 contain the ilvIH gene derived from *Escherichia coli* (as shown in SEQ ID NO:4). Specifically, recombinant bacteria YPI-003 is obtained by replacing the coding region of the poxB gene (GeneID: 1020557, 12-Dec-2025) in the genome of *Corynebacterium glutamicum* CGMCC No. 20437 (i.e., the fragment located between SEQ ID NO:16 and SEQ ID NO:17) with the ORF and trc promoter region of the ilvIH gene from *E. coli* (i.e., SEQ ID NO:19), while keeping other nucleotides in the genome of *Corynebacterium glutamicum* CGMCC No. 20437 unchanged. The recombinant strain YPI-004 is obtained by replacing the coding region of the poxB gene (GeneID: 1020557, 12-Dec-2025) in the genome of Corynebacterium glutamicum ATCC 13032 (i.e., the fragment located between SEQ ID NO:16 and SEQ ID NO:17) with the ORF of the ilvIH gene and the trc promoter region (i.e., SEQ ID NO:19) from Escherichia coli, while keeping other nucleotides in the genome of Corynebacterium glutamicum ATCC 13032 unchanged.
[0076] Single colonies generated from the culture of the pK18-ilvIHOE-Kp recombinant plasmid were identified by PCR using primers P15 / P21. Strains amplified with a fragment of 1108 bp were considered positive, while those without amplification were considered the original strain. Positive strains were cultured on medium containing 15% sucrose, and single colonies were further identified by PCR using primers P22 / P18. Strains amplified with a fragment of 1151 bp were considered positive. Positive strains of *Klebsiella pneumoniae* with *ilvIH* gene integrated into *Corynebacterium glutamicum* CGMCC No. 20437 and ATCC 13032 were named YPI-005 and YPI-006, respectively.
[0077] Both recombinant bacteria YPI-005 and YPI-006 contain the ilvIN gene derived from Klebsiella pneumoniae (as shown in SEQ ID NO:7). Specifically, recombinant bacteria YPI-005 is obtained by replacing the coding region of the poxB gene (GeneID: 1020557, 12-Dec-2025) in the genome of Corynebacterium glutamicum CGMCC No.20437 (i.e., the fragment located between SEQ ID NO:16 and SEQ ID NO:17) with the ORF and trc promoter region of the ilvIN gene derived from Klebsiella pneumoniae (i.e., SEQ ID NO:20), while keeping other nucleotides in the genome of Corynebacterium glutamicum CGMCC No.20437 unchanged. The recombinant strain YPI-006 is obtained by replacing the coding region of the poxB gene (GeneID: 1020557, 12-Dec-2025) in the genome of Corynebacterium glutamicum ATCC 13032 (i.e., the fragment located between SEQ ID NO:16 and SEQ ID NO:17) with the ORF of the ilvIN gene and the trc promoter region (i.e., SEQ ID NO:20) from Klebsiella pneumoniae, while keeping other nucleotides in the genome of Corynebacterium glutamicum ATCC 13032 unchanged.
[0078] Single colonies generated from the culture of the pK18-ilvIHOE-Sm recombinant plasmid were identified by PCR using primers P15 / P23. Strains amplified with a fragment of 1108 bp were considered positive, while those without amplification were considered the original strain. Positive strains were cultured on medium containing 15% sucrose, and single colonies were further identified by PCR using primers P24 / P18. Strains amplified with a fragment of 1151 bp were considered positive. Positive strains of *Serratia marcescens* with the ilvIN gene integrated into *Corynebacterium glutamicum* CGMCC No. 20437 and ATCC 13032 were named YPI-007 and YPI-008, respectively.
[0079] Both recombinant bacteria YPI-007 and YPI-008 contain the ilvIN gene from *Serratia marcescens* (as shown in SEQ ID NO:10). Specifically, recombinant bacteria YPI-007 is obtained by replacing the coding region of the poxB gene (GeneID: 1020557, 12-Dec-2025) in the genome of *Corynebacterium glutamicum* CGMCC No.20437 (i.e., the fragment located between SEQ ID NO:16 and SEQ ID NO:17) with the ORF of the ilvIN gene and the trc promoter region (i.e., SEQ ID NO:21) from *Corynebacterium glutamicum* CGMCC No.20437, while keeping other nucleotides in the genome of *Corynebacterium glutamicum* CGMCC No.20437 unchanged. The recombinant strain YPI-008 is obtained by replacing the coding region of the poxB gene (GeneID: 1020557, 12-Dec-2025) in the genome of Corynebacterium glutamicum ATCC 13032 (i.e., the fragment located between SEQ ID NO:16 and SEQ ID NO:17) with the ORF of the ilvIN gene and the trc promoter region (i.e., SEQ ID NO:21) from Serratia marcescens, while keeping other nucleotides in the genome of Corynebacterium glutamicum ATCC 13032 unchanged.
[0080] Single colonies generated from the culture of the pK18-ilvIHOE-Mt recombinant plasmid were identified by PCR using primers P15 / P25. Strains amplified with a fragment of 1108 bp were considered positive, while those without amplification were considered the original bacteria. Positive strains were cultured on medium containing 15% sucrose, and single colonies were further identified by PCR using primers P26 / P18. Strains amplified with a fragment of 1151 bp were considered positive. Positive strains of *Corynebacterium tuberculosis* CGMCC No. 20437 and ATCC 13032, resulting from the integration of the *Mycobacterium tuberculosis* ilvB1 and ilvN genes, were named YPI-009 and YPI-010, respectively.
[0081] Both recombinant bacteria YPI-009 and YPI-010 contain the ilvB1 and ilvN genes derived from Mycobacterium tuberculosis (as shown in SEQ ID NO:13). Specifically, recombinant bacteria YPI-009 is obtained by replacing the coding region of the poxB gene (GeneID: 1020557, 12-Dec-2025) in the genome of Corynebacterium glutamicum CGMCC No.20437 (i.e., the fragment located between SEQ ID NO:16 and SEQ ID NO:17) with the ORF and trc promoter regions of the ilvB1 and ilvN genes derived from Mycobacterium tuberculosis (i.e., SEQ ID NO:22), while keeping other nucleotides in the genome of Corynebacterium glutamicum CGMCC No.20437 unchanged. The recombinant strain YPI-010 is obtained by replacing the coding region of the poxB gene (GeneID:1020557, 12-Dec-2025) in the genome of Corynebacterium glutamicum ATCC 13032 (i.e., the fragment located between SEQ ID NO:16 and SEQ ID NO:17) with the ilvB1 gene and ilvN gene ORF and trc promoter region (i.e., SEQ ID NO:22) from Mycobacterium tuberculosis, while keeping other nucleotides in the genome of Corynebacterium glutamicum ATCC 13032 unchanged.
[0082] The PCR identification primers are shown below: P15: 5'-GCCAGAAAATGGGTTGCGTGA-3'; P16: 5'-GCCGTCGGCCATATGGGTAG-3'; P17: 5'-TGATGCTGGTGAAGGTCAAGGCC-3'; P18: 5'-TCAAACGTAATGCGGATCAG-3'; P19: 5'-GCCATCGGCCATATGCACCGCC-3'; P20: 5'-TCATGCTGTGAAAATTCAGGCCAG-3'; P21: 5'-GACCTCCCCGGTCGCCCGCGCCA-3'; P22: 5'-TTATGCTGGTGAAGGTTCAGGCCAG-3'; P23: 5'-ACCGTCAGCCATGTGCACCGC-3'; P24: 5'-TCATGCTGGTGAAGCTGCAGG-3'; P25: 5'-CGGAATCCCGAAAATGACGTCG-3'; P26: 5'-TCATCAAGGTCCAAGCCGACGC-3'.
[0083] Example 3: L-Isoleucine Fermentation Experiment The strains constructed in the above examples, along with the original strains *Corynebacterium glutamicum* CGMCC 20437 and ATCC 13032, were fermented in a BLBIO-5GC-4-H fermenter (Shanghai Bailun Biotechnology Co., Ltd.) using the fermentation medium described below and the control process shown in Table 2. Each strain was replicated three times, and the results are shown in Table 3.
[0084] The fermentation medium formula is as follows: glucose 5.0 g / L, phosphate 0.38 g / L, magnesium sulfate 1.85 g / L, potassium chloride 1.6 g / L, biotin 550 μg / L, vitamin biotin B1 300 μg / L, ferrous sulfate 10 mg / L, manganese sulfate 10 g / dL, KH2PO4 2.8 g / L, vitamin C 0.75 mg / L, vitamin B12 2.5 μg / L, para-aminobenzoic acid 0.75 mg / L, antifoaming agent 0.0015 ml / dL, betaine 1.5 g / L, sugarcane molasses 7 ml / L, corn steep liquor 77 ml / L, aspartic acid 1.7 g / L, hair powder 2 g / L, and water as the solvent.
[0085] The results are shown in Table 3. Overexpression of the acetolactate synthase gene (ilvIH) derived from Pseudomonas aeruginosa and Escherichia coli in Corynebacterium glutamicum significantly increased L-isoleucine production, and the overexpression of the acetolactate synthase gene (ilvIH) derived from Pseudomonas aeruginosa had a more significant effect on L-isoleucine production; other heterologous acetolactate synthase genes had no significant effect on L-isoleucine production.
[0086] Table 2. Fermentation Control Process
[0087] Table 3. Results of L-Isoleucine Fermentation Experiment
[0088] Note: The P-values of strains YPI-001, YPI-003, YPI-005, YPI-007, and YPI-009 are compared with CGMCC No. 20437. The P-values of strains YPI-002, YPI-004, YPI-006, YPI-008, and YPI-010 are compared with ATCC 13032.
[0089] The present invention has been described in detail above. Those skilled in the art will recognize that the invention can be practiced in a wide range of ways with equivalent parameters, concentrations, and conditions without departing from its spirit and scope, and without requiring unnecessary experiments. While specific embodiments have been provided, it should be understood that further modifications can be made to the invention. In summary, according to the principles of the invention, this application is intended to include any changes, uses, or improvements to the invention, including changes made using conventional techniques known in the art that depart from the scope disclosed herein.
Claims
1. Recombinant Corynebacterium glutamicum, characterized in that: The recombinant Corynebacterium glutamicum includes the expression of heterologous acetolactate synthase; the heterologous acetolactate synthase is acetolactate synthase derived from Pseudomonas aeruginosa or acetolactate synthase derived from Escherichia coli.
2. The recombinant Corynebacterium glutamicum according to claim 1, characterized in that: The acetolactate synthase derived from *Pseudomonas aeruginosa* comprises any one of the following (A1)-(A4): (A1) is composed of a large catalytic subunit containing SEQ ID NO:2 in its amino acid sequence and a small regulatory subunit containing SEQ ID NO:3 in its amino acid sequence; (A2) is formed by the catalytic large subunit and the regulatory small subunit defined by (A1) through the substitution, deletion and / or addition of one or more amino acid residues, and retains the acetolactate synthase activity of the large and small subunits. (A3) consists of a large subunit and a small subunit that have at least 90% sequence identity with the amino acid sequence defined by (A1) or (A2) and retain acetolactate synthase activity; (A4) consists of two fusion proteins obtained by linking tag sequences to the N-terminus and / or C-terminus of the large and small subunits as defined in any of (A1) to (A3); The acetolactate synthase derived from *E. coli* comprises any one of the following (B1)-(B4): (B1) is composed of a large catalytic subunit containing SEQ ID NO:5 in its amino acid sequence and a small regulatory subunit containing SEQ ID NO:6 in its amino acid sequence; (B2) is formed by replacing, deleting and / or adding one or more amino acid residues of the catalytic large subunit and the regulatory small subunit defined in (B1), and retaining the acetolactate synthase activity of the large and small subunits. (B3) consists of a large subunit and a small subunit that have at least 90% sequence identity with the amino acid sequence defined by (B1) or (B2) and retain acetolactate synthase activity. (B4) consists of two fusion proteins obtained by linking tag sequences to the N-terminus and / or C-terminus of the large and small subunits as defined in any of (B1) to (B3).
3. The recombinant Corynebacterium glutamicum according to claim 1 or 2, characterized in that: The recombinant Corynebacterium glutamicum includes: the recombinant bacteria obtained by introducing the encoding gene of the heterologous acetolactate synthase into the recipient Corynebacterium glutamicum.
4. The recombinant Corynebacterium glutamicum according to claim 3, characterized in that: The gene encoding the heterologous acetolactate synthase includes any of the following: (C1) A DNA molecule whose nucleotide sequence contains SEQ ID NO:1 or whose nucleotide sequence contains SEQ ID NO:4; (C2) A DNA molecule that hybridizes under stringent conditions with the DNA molecule defined by (C1) and encodes the heterologous acetolactate synthase; The DNA molecule that has 99%, 95%, 90%, 85% or more or 80% identity with the DNA sequence defined by (C3) and (C1) or (C2) and encodes the heterologous acetolactate synthase.
5. The use of the recombinant Corynebacterium glutamicum according to any one of claims 1-4 in the fermentation production of L-isoleucine.
6. The application of heterologous acetolactate synthase or related biological materials in the preparation or production of L-isoleucine; wherein the heterologous acetolactate synthase is acetolactate synthase derived from Pseudomonas aeruginosa or acetolactate synthase derived from Escherichia coli.
7. The application according to claim 6, characterized in that, The acetolactate synthase derived from *Pseudomonas aeruginosa* comprises any one of the following (A1)-(A4): (A1) is composed of a large catalytic subunit containing SEQ ID NO:2 in its amino acid sequence and a small regulatory subunit containing SEQ ID NO:3 in its amino acid sequence; (A2) is formed by the catalytic large subunit and the regulatory small subunit defined by (A1) through the substitution, deletion and / or addition of one or more amino acid residues, and retains the acetolactate synthase activity of the large and small subunits. (A3) consists of a large subunit and a small subunit that have at least 90% sequence identity with the amino acid sequence defined by (A1) or (A2) and retain acetolactate synthase activity; (A4) consists of two fusion proteins obtained by linking tag sequences to the N-terminus and / or C-terminus of the large and small subunits as defined in any of (A1) to (A3); The acetolactate synthase derived from *E. coli* comprises any one of the following (B1)-(B4): (B1) is composed of a large catalytic subunit containing SEQ ID NO:5 in its amino acid sequence and a small regulatory subunit containing SEQ ID NO:6 in its amino acid sequence; (B2) is formed by replacing, deleting and / or adding one or more amino acid residues of the catalytic large subunit and the regulatory small subunit defined in (B1), and retaining the acetolactate synthase activity of the large and small subunits. (B3) consists of a large subunit and a small subunit that have at least 90% sequence identity with the amino acid sequence defined by (B1) or (B2) and retain acetolactate synthase activity. (B4) consists of two fusion proteins obtained by linking tag sequences to the N-terminus and / or C-terminus of the large and small subunits as defined in any of (B1) to (B3).
8. A method for constructing engineered bacteria for producing L-isoleucine, comprising the following steps: expressing heterologous acetolactate synthase in a recipient, Corynebacterium glutamicum; wherein the heterologous acetolactate synthase is acetolactate synthase derived from Pseudomonas aeruginosa or acetolactate synthase derived from Escherichia coli.
9. The method according to claim 8, characterized in that, The acetolactate synthase derived from *Pseudomonas aeruginosa* comprises any one of the following (A1)-(A4): (A1) is composed of a large catalytic subunit containing SEQ ID NO:2 in its amino acid sequence and a small regulatory subunit containing SEQ ID NO:3 in its amino acid sequence; (A2) is formed by the catalytic large subunit and the regulatory small subunit defined by (A1) through the substitution, deletion and / or addition of one or more amino acid residues, and retains the acetolactate synthase activity of the large and small subunits. (A3) consists of a large subunit and a small subunit that have at least 90% sequence identity with the amino acid sequence defined by (A1) or (A2) and retain acetolactate synthase activity; (A4) consists of two fusion proteins obtained by linking tag sequences to the N-terminus and / or C-terminus of the large and small subunits as defined in any of (A1) to (A3); The acetolactate synthase derived from *E. coli* comprises any one of the following (B1)-(B4): (B1) is composed of a large catalytic subunit containing SEQ ID NO:5 in its amino acid sequence and a small regulatory subunit containing SEQ ID NO:6 in its amino acid sequence; (B2) is formed by replacing, deleting and / or adding one or more amino acid residues of the catalytic large subunit and the regulatory small subunit defined in (B1), and retaining the acetolactate synthase activity of the large and small subunits. (B3) consists of a large subunit and a small subunit that have at least 90% sequence identity with the amino acid sequence defined by (B1) or (B2) and retain acetolactate synthase activity. (B4) consists of two fusion proteins obtained by linking tag sequences to the N-terminus and / or C-terminus of the large and small subunits as defined in any of (B1) to (B3).
10. A method for producing L-isoleucine, comprising the following steps: fermenting and culturing the recombinant Corynebacterium glutamicum according to any one of claims 1-4, and obtaining L-isoleucine from the fermentation product.
